Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,992,349
  • Shares Outstanding, K 36,550
  • Annual Sales, $ 20,180 K
  • Annual Income, $ -123,650 K
  • 36-Month Beta 3.38
  • Price/Sales 146.29
  • Price/Cash Flow 0.00
  • Price/Book 11.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.64 +6.81%
on 10/20/17
91.75 -8.45%
on 10/13/17
-1.15 (-1.36%)
since 09/22/17
3-Month
66.52 +26.27%
on 08/01/17
91.75 -8.45%
on 10/13/17
+14.98 (+21.70%)
since 07/21/17
52-Week
35.07 +139.51%
on 11/03/16
91.75 -8.45%
on 10/13/17
+31.58 (+60.23%)
since 10/21/16

Most Recent Stories

More News
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

ONCE : 84.74 (+3.51%)
IMDZ : 5.20 (-0.96%)
IONS : 63.85 (-0.84%)
EXEL : 27.17 (+0.04%)
REGN : 434.75 (+0.41%)
ALXN : 136.21 (-2.02%)
BIIB : 330.12 (-2.36%)
Biotech Stocks on Investors' Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics

If you want a Stock Review on NKTR, OPHT, PTCT, or ONCE then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Friday, October 13, 2017, US markets saw...

PTCT : 17.29 (-2.81%)
ONCE : 84.74 (+3.51%)
OPHT : 2.36 (-2.07%)
NKTR : 24.41 (+1.03%)
FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA(TM) (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease

Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States

ONCE : 84.74 (+3.51%)
Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that NASDAQ has halted trading of its common stock....

ONCE : 84.74 (+3.51%)
Spark Therapeutics Stock Sees Short Interest Fall 48%

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 2,088,336 share decrease in total short interest for Spark Therapeutics Inc , to 2,255,175, a decrease...

ONCE : 84.74 (+3.51%)
Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Federico Mingozzi, Ph.D., as...

ONCE : 84.74 (+3.51%)
Spark Therapeutics Enters into Licensing Agreement with Genethon

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into a licensing agreement with Genethon,...

ONCE : 84.74 (+3.51%)
Spark Therapeutics Announces Publication of Study Confirming Novel Test's Validity, Reliability and Ability to Detect Change in Functional Vision

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that Clinical and Experimental Ophthalmology, a...

ONCE : 84.74 (+3.51%)
Spark Therapeutics to Participate in Multiple Conferences in September

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that company management will present at or attend...

ONCE : 84.74 (+3.51%)
Spark Therapeuti Up 37.7% Since SmarTrend Uptrend Call (ONCE)

SmarTrend identified an Uptrend for Spark Therapeuti (NASDAQ:ONCE) on June 14th, 2017 at $56.68. In approximately 2 months, Spark Therapeuti has returned 37.75% as of today's recent price of $78.07.

ONCE : 84.74 (+3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Support & Resistance

2nd Resistance Point 84.34
1st Resistance Point 83.11
Last Price 84.74
1st Support Level 79.64
2nd Support Level 77.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart